

1 **Viral dynamics of SARS-CoV-2 variants in vaccinated and unvaccinated individuals**

2
3 Stephen M. Kissler*¹, Joseph R. Fauver*², Christina Mack*^{3,4}, Caroline G. Tai³, Mallery I.
4 Breban², Anne E. Watkins², Radhika M. Samant³, Deverick J. Anderson⁵, Jessica Metti⁶, Gaurav
5 Khullar⁶, Rachel Baits⁶, Matthew MacKay⁶, Daisy Salgado⁶, Tim Baker⁶, Joel T. Dudley⁶, Chris-
6 topher E. Mason⁶, David D. Ho⁷, Nathan D. Grubaugh^{†2}, Yonatan H. Grad^{†1}

7
8 ¹ Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public
9 Health, Boston, MA

10 ² Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven,
11 CT

12 ³ IQVIA, Real World Solutions, Durham, NC

13 ⁴ Department of Epidemiology, University of North Carolina-Chapel Hill, Chapel Hill, NC

14 ⁵ Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham, NC

15 ⁶ TEMPUS Labs, Chicago, IL

16 ⁷ Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians
17 and Surgeons, New York, NY

18
19
20 * denotes equal contribution

21 † denotes co-senior authorship

22
23 Correspondence and requests for materials should be addressed to:

24 Email: ygrad@hsph.harvard.edu

25 Telephone: 617.432.2275

27 **Abstract.**

28

29 **Background.** The alpha and delta SARS-CoV-2 variants have been responsible for major recent
30 waves of COVID-19 despite increasing vaccination rates. The reasons for the increased trans-
31 missibility of these variants and for the reduced transmissibility of vaccine breakthrough infections
32 are unclear.

33

34 **Methods.** We quantified the course of viral proliferation and clearance for 173 individuals with
35 acute SARS-CoV-2 infections using longitudinal quantitative RT-PCR tests conducted using an-
36 terior nares/oropharyngeal samples ($n = 199,941$) as part of the National Basketball Association's
37 (NBA) occupational health program between November 28th, 2020, and August 11th, 2021. We
38 measured the duration of viral proliferation and clearance and the peak viral concentration sepa-
39 rately for individuals infected with alpha, delta, and non-variants of interest/variants of concern
40 (non-VOI/VOC), and for vaccinated and unvaccinated individuals.

41

42 **Results.** The mean viral trajectories of alpha and delta infections resembled those of non-
43 VOI/VOC infections. Vaccine breakthrough infections exhibited similar proliferation dynamics as
44 infections in unvaccinated individuals (mean peak Ct: 20.5, 95% credible interval [19.0, 21.0] vs.
45 20.7 [19.8, 20.2], and mean proliferation time 3.2 days [2.5, 4.0] vs. 3.5 days [3.0, 4.0]); however,
46 vaccinated individuals exhibited faster clearance (mean clearance time: 5.5 days [4.6, 6.6] vs. 7.5
47 days [6.8, 8.2]).

48

49 **Conclusions.** Alpha, delta, and non-VOI/VOC infections feature similar viral trajectories. Acute
50 infections in vaccinated and unvaccinated people feature similar proliferation and peak Ct, but
51 vaccinated individuals cleared the infection more quickly. Viral concentrations do not fully explain
52 the differences in infectiousness between SARS-CoV-2 variants, and mitigation measures are
53 needed to limit transmission from vaccinated individuals.

54

55 Two opposing forces shaping the COVID-19 pandemic are (1) the emergence of increasingly
56 transmissible SARS-CoV-2 variants of concern (VOCs) and (2) the uptake of vaccines that pre-
57 vent infection, protect against severe disease, and reduce transmission. Among the VOCs, of
58 special interest are the alpha (lineage B.1.1.7) and delta (B.1.617.2, AY.1, AY.2, AY.3, and
59 AY.3.1) variants, responsible for recent waves of COVID-19.¹ These variants feature mutations
60 in the spike protein receptor binding domain² that may enhance ACE-2 binding,³ thus increasing
61 the efficiency of virus transmission. In addition to, and perhaps due to, these attributes, the viral
62 trajectories for infections with alpha and delta could feature a higher peak viral load or longer
63 duration of carriage, both of which could increase transmissibility. Meanwhile, preliminary evi-
64 dence suggests that individuals with vaccine breakthrough infections are less likely to transmit,^{4,5}
65 but whether this is attributable to lower peak viral loads, shorter duration of carriage, or both,
66 remains uncertain.

67
68 By measuring viral concentration over the course of acute infection, it is possible to inform hy-
69 potheses about the mechanisms that underlie variation in transmissibility. Recent evidence sug-
70 gests that delta-variant infections may feature substantially higher peak viral concentrations rela-
71 tive to other lineages,⁶ while viral concentrations in alpha-variant infections were indistinguishable
72 from non-variant infections.⁷ Vaccinated individuals who become infected with SARS-CoV-2 may
73 clear their infections more quickly than unvaccinated individuals,⁸ and vaccine breakthrough in-
74 fections with delta may feature similar peak viral concentrations as non-breakthrough delta infec-
75 tions.⁹ However, many of these studies rely on cross-sectional viral concentration measurements
76 triggered by the onset of symptoms, which miss viral dynamics during the critical early stages of
77 infection. Furthermore, population transmission dynamics can bias cross-sectional viral concen-
78 tration measurements,¹⁰ making it difficult to compare viral concentrations between variants that
79 emerged at different periods of the pandemic.

80
81 To overcome these limitations, we collected and analyzed a prospective, longitudinal set of
82 SARS-CoV-2 viral samples from 173 individuals obtained as part of the National Basketball As-
83 sociation's occupational health program. Using a Bayesian hierarchical statistical model, we com-
84 pared SARS-CoV-2 viral dynamics between individuals infected with alpha, delta, and non-vari-
85 ants of interest/variants of concern (non-VOI/VOCs) as well as for vaccinated and unvaccinated
86 individuals.

87

88 **Methods.**

89

90 Study design. The data reported here represent a convenience sample including team staff,
91 players, arena staff, and other vendors (e.g., transportation, facilities maintenance, and food
92 preparation) affiliated with the National Basketball Association (NBA). The study period ran be-
93 tween November 28th, 2020, and August 11th, 2021. Clinical samples were obtained by combined
94 swabs of the anterior nares and oropharynx administered by a trained provider. Viral
95 concentration was measured using the cycle threshold (Ct) according to the Roche cobas target
96 1 assay. Ct values were converted to viral genome equivalents using a standard curve
97 **(Supplementary methods).**

98

99 Study oversight. In accordance with the guidelines of the Yale Human Investigations Committee,
100 this work with de-identified samples was approved for research not involving human subjects by
101 the Yale Institutional Review Board (HIC protocol # 2000028599). This project was designated
102 exempt by the Harvard Institutional Review Board (IRB20-1407).

103

104 Study participants. Out of an initial pool of 872 participants who tested positive for SARS-CoV-2
105 infection during the study period, 173 individuals (90% male) had clinically confirmed novel
106 infections that met our inclusion criteria: at least three positive PCR tests (Ct < 40), at least one
107 negative PCR test (Ct = 40), and at least one test with Ct < 32 with the first positive test (Ct < 40)
108 occurring before August 1st to ensure full sampling of the trajectory before the end of the study
109 period. **(Table 1)**. A total of 19,941 samples were available for this cohort, averaging 548 samples
110 per week. Of the individuals who met the inclusion criteria, 36 were infected with alpha (B.1.1.7)
111 and 36 with delta (B.1.617.2, AY.1, AY.2, AY.3, or AY.3.1), as confirmed by sequencing. An
112 additional 28 individuals were infected with other variants of interest/variants of concern. There
113 were 37 individuals with vaccine breakthrough infections, defined as infections for which the first
114 positive test occurred at least two weeks after receipt of the final dose. Of these, 23 received the
115 Pfizer-BioNTech vaccine, 8 received the Johnson & Johnson/Janssen vaccine, and 3 received
116 the Moderna vaccine. The vaccine manufacturer was not reported for the remaining 3 individuals.

117

118 Study outcomes. We quantified the viral proliferation duration (time from first possible detection
119 to peak viral concentration) the viral clearance duration (time from peak viral concentration to
120 clearance of acute infection), the duration of acute infection (proliferation duration plus clearance

121 duration), and the peak viral concentration for each person. We also quantified the population
122 mean values of these quantities separately for individuals infected with alpha ($n = 36$), delta ($n =$
123 36), and non-VOI/VOCs ($n = 41$), as well as for vaccinated ($n = 37$) and unvaccinated ($n = 136$)
124 individuals.

125
126 Genome sequencing and lineage assignments. RNA was extracted and confirmed as SARS-CoV-
127 2 positive by RT-qPCR with the Thermo Fisher TaqPath SARS-CoV-2 assay.¹¹ Next Generation
128 Sequencing with the Illumina COVIDSeq ARTIC primer set¹² was used for viral amplification. Li-
129 brary preparation was performed using the amplicon-based Illumina COVIDseq Test v03¹³ and
130 sequenced 2x74 on Illumina NextSeq 550 following the protocol as described in Illumina's docu-
131 mentation.¹⁴ The resulting FASTQs were processed and analyzed on Illumina BaseSpace Labs
132 using the Illumina DRAGEN COVID Lineage Application;¹⁵ versions included are 3.5.0, 3.5.1,
133 3.5.2, and 3.5.3. The DRAGEN COVID Lineage pipeline was run with default parameters recom-
134 mended by Illumina. Samples were considered SARS-COV-2 positive if at least 5 viral amplicon
135 targets were detected at 20x coverage. Each SARS-COV-2 positive sample underwent lineage
136 assignment and phylogenetics analysis using the most updated version of Pangolin¹⁶ and
137 NextClade,¹⁷ respectively.

138
139 Statistical analysis. Following previously described methods,¹⁸ we used a Bayesian hierarchical
140 model to estimate the proliferation duration, clearance duration, and peak viral concentration for
141 each person and for the sub-populations of interest. The model describes the \log_{10} viral concen-
142 tration during an acute infection using a continuous piecewise-linear curve with control points that
143 specify the time of acute infection onset, the time and magnitude of peak viral concentration, and
144 the time of acute infection clearance. The assumption of piecewise linearity is equivalent to as-
145 suming exponential viral growth during the proliferation period followed by exponential viral decay
146 during the clearance period. The control points were inferred using the Hamiltonian Monte Carlo
147 algorithm as implemented in Stan (version 2.24).¹⁹ We used priors informed by a previous
148 analysis¹⁸ for the main analysis and conducted a sensitivity analysis using vague priors as well
149 as a strongly biased set of priors to assess robustness to the choice of prior. Full details are given
150 in the **Supplementary methods**. Data and code are available online.²⁰

151

152 **Results.**

153 Summary of viral concentration measurements and model fit. A median of 6 samples (IQR: [4, 9])
154 with Ct values that surpassed the limit of detection (Ct = 40) were recorded for each person. The
155 raw viral concentration measurements are depicted in **Figure 1** for individuals infected with alpha,
156 delta, and non-VOI/VOCs as well as for unvaccinated and vaccinated infected individuals. Many
157 of the tail samples depicted in **Figure 1** reflect samples with high Ct value/low viral concentration
158 after the conclusion of acute infection. As these were not the main object of study in this analysis,
159 any tests that occurred after the conclusion of an individual's acute infection (as specified by the
160 statistical model) are depicted in lighter shades. Visually, the trajectories appear similar across
161 variants and vaccination statuses. While there are fewer low-level positives following acute infec-
162 tion for those with vaccine breakthrough and delta infections, this may reflect the fact that delta
163 and breakthrough infections were more likely to occur near the end of the study period, which
164 may have led to censoring of these points, as well as the substantial overlap in these categories
165 (see **Table 1**). The individual-level model fits are depicted **Supplementary Figures 1-9**. The
166 Gelman R-hat statistic²¹ was less than 1.1 for all parameters, indicating good convergence. There
167 were no divergent iterations, indicating good exploration of the parameter space.

168
169 Viral trajectories by variant. We found no difference in the mean peak viral concentration, prolif-
170 eration duration, clearance duration, or duration of acute infection for alpha or delta relative to
171 non-VOI/VOCs, as evidenced by overlapping 95% credible intervals (**Figure 2A-F, Supplemen-**
172 **tary Table 1**). However, delta infections featured more frequent low peak Ct values, and corre-
173 sponding high peak viral concentrations, than alpha or non-VOI/VOC infections, with 13.0% of
174 the posterior delta trajectories surpassing a Ct value of 15 (9.6 log₁₀ RNA copies/ml) vs. 6.9% and
175 10.2% of the posterior alpha and non-VOI/VOC trajectories surpassing the same threshold (**Fig-**
176 **ure 2G**). For those infected with delta, there is some evidence that vaccinated individuals tended
177 to clear the virus more quickly than unvaccinated individuals (mean 5.9 days (95% credible inter-
178 val [4.8, 7.2]) in vaccinated individuals vs. 7.6 days [5.5, 10.1] in unvaccinated individuals; **Sup-**
179 **plementary Figure 10**), though the sample sizes are small and the 95% credible intervals for the
180 mean clearance duration overlap.

181
182 Viral trajectories by vaccination status. We found no difference in the mean peak viral concentra-
183 tion or proliferation duration between vaccinated and unvaccinated individuals as evidenced by
184 overlapping 95% credible intervals (**Figure 3**). However, breakthrough infections featured a faster
185 clearance time (mean 5.5 days [4.6, 6.5] vs. 7.5 days [6.8, 8.2] in unvaccinated individuals),

186 leading to a shorter overall duration of infection (8.7 days [7.6, 9.9] in vaccinated individuals vs.
187 11.0 days [10.3, 11.8] in unvaccinated individuals). We found no difference in viral trajectories for
188 infected individuals who received the Pfizer-BioNTech vaccine ($n = 23$) vs. the Johnson & John-
189 son/Janssen vaccine ($n = 8$; **Supplementary Figure 11**). We did not assess viral trajectories for
190 breakthrough infections in individuals who received the Moderna vaccine due to the small sample
191 size ($n = 3$).

192

193 **Discussion.**

194 With the emergence of more transmissible SARS-CoV-2 variants such as alpha and delta, a key
195 goal has been to understand which factors contribute to increased transmissibility. Our results
196 indicate that the viral dynamics of infections caused by the alpha variant resemble those caused
197 by the founding SARS-CoV-2 lineages, with similar proliferation and clearance times and similar
198 peak viral concentrations. Viral dynamics in the oropharynx and nasopharynx therefore do not
199 explain the elevated transmissibility of the alpha variant relative to the founding SARS-CoV-2
200 lineages.²² Instead, other factors, such as enhanced receptor binding which could lower the viral
201 dose required for infection, may contribute to the alpha variant's increased transmissibility. The
202 viral dynamics of the delta variant are similar, with the exception that infections caused by the
203 delta variant appear more likely to feature high peak viral concentrations. It is unclear if the greater
204 proportion of cases with high peak viral concentrations reflects the underlying biology of the delta
205 variant, the limited number of cases and sampling, or other factors, including the higher fraction
206 of delta infections that were in vaccinated individuals. Infections with unusually high peak viral
207 concentration may play an outsized role in spreading the virus, either by increasing the risk of
208 transmission outside of close-contact settings²³ or increasing the likelihood of "superspreading"
209 events, pointing towards a possible mechanism for the enhanced transmissibility of the delta var-
210 iant. Upper respiratory viral concentrations also do not explain the possible enhanced pathogenic-
211 ity of the alpha and delta variants.²⁴ Further studies are needed to uncover the origins of any
212 differences in virulence, which could stem from differences in systemic viral dynamics that are not
213 captured by oropharyngeal/nasopharyngeal samples.

214

215 A second key objective is to define the impact of COVID-19 vaccines on viral dynamics. Strong
216 evidence demonstrates that each of the vaccines used by individuals in this cohort—the Pfizer/Bi-
217 oNTech, Moderna, and Johnson & Johnson/Janssen vaccines—reduces the rates of symptomatic
218 COVID-19.^{25–27} A growing body of data also suggests that these vaccines reduce rates of

219 asymptomatic infection.^{28–30} The extent to which infected vaccinated people can transmit SARS-
220 CoV-2 has been unclear, with recent data supporting that breakthrough infections are infectious.⁹
221 Our data and a recent report from Singapore⁸ show that vaccine breakthrough cases follow a
222 similar proliferation phase and reach similar peak viral concentrations as unvaccinated cases, but
223 have a more rapid clearance phase, thereby modestly shortening the overall duration of infection.
224 If the Ct values in vaccinated and unvaccinated infected individuals reflect the same amounts of
225 infectious virus, then this implies that individuals with breakthrough infections may be as infectious
226 as unvaccinated individuals in the early stage of the infection, but remain infectious for a shorter
227 time, reducing the total degree of onward transmission. These findings are in keeping with the
228 hypothesis that vaccination protects against the severe manifestations of disease but offers less
229 protection against infection in the upper airway. Precautions are therefore necessary to prevent
230 onward transmission even from vaccinated individuals.

231
232 Our ability to detect differences in SARS-CoV-2 viral dynamics between key populations was
233 limited by small sample sizes and a high degree of interpersonal variation. More prospective lon-
234 gitudinal testing data within diverse cohorts is urgently needed to help resolve these patterns,
235 particularly the peak viral concentration distribution for delta infections. The participants in this
236 study were predominately young, male, and healthy, and therefore not representative across the
237 general population. This underscores the need for similar studies in more diverse cohorts. Symp-
238 toms were not tracked throughout infection in this observational cohort; we were unable to assess
239 differences in viral dynamics between symptomatic and asymptomatic individuals, nor were we
240 able to link the timing of symptoms with key points in the viral trajectories. We did not test for the
241 presence of infectious virus. While high viral concentrations are associated with elevated infec-
242 tiousness,³¹ the nature of this association may be influenced by multiple factors, including variant,
243 vaccination status, immune function, and host genetics.³² Viral culture studies and patient data
244 would therefore help to contextualize the findings presented in this study.

245
246 This study provides a detailed picture of acute SARS-CoV-2 viral dynamics for key variants of
247 concern in vaccinated and unvaccinated individuals. Frequent longitudinal measurements of viral
248 concentrations can play a valuable role in illuminating factors contributing to SARS-CoV-2 trans-
249 missibility and the nature and extent of the impact of vaccination on viral dynamics in acute infec-
250 tions, thus informing interventions needed to mitigate the impact of COVID-19.

251

	Alpha (%)	Delta (%)	Other VOI/VVOC (%)	Non- VOI/VOC (%)	Not genotyped (%)	Total (%)
Total	36 (20.8)	36 (20.8)	28 (16.2)	41 (23.7)	32 (18.5)	173 (100)
Age						
<18	3 (1.7)	2 (1.2)	2 (1.2)	0 (0)	1 (0.6)	8 (4.6)
18-29	23 (13.3)	6 (3.5)	13 (7.5)	26 (15)	11 (6.4)	79 (45.7)
30-39	4 (2.3)	8 (4.6)	6 (3.5)	7 (4.0)	6 (3.5)	31 (17.9)
40-49	4 (2.3)	14 (8.1)	4 (2.3)	3 (1.7)	5 (2.9)	30 (17.3)
50-59	2 (1.2)	4 (2.3)	1 (0.6)	2 (1.2)	4 (2.3)	13 (7.5)
≥60	0 (0)	2 (1.2)	2 (1.2)	3 (1.7)	5 (2.9)	12 (6.9)
Symptoms reported						
No	18 (10.4)	23 (13.3)	15 (8.7)	22 (12.7)	24 (13.9)	102 (59.0)
Yes	18 (10.4)	13 (7.5)	13 (7.5)	19 (11.0)	8 (4.6)	71 (41.0)
Vaccine breakthrough						
No	32 (18.5)	11 (6.4)	25 (14.5)	41 (23.7)	27 (15.6)	136 (78.6)
Yes	4 (2.3)	25 (14.5)	3 (1.7)	0 (0)	5 (2.9)	37 (21.4)

252
253
254
255
256

Table 1. Characteristics of the study population. Number and percent (in parentheses) of individuals in the study population by age group, reported symptoms, and vaccine breakthrough status, stratified by variant.





Figure 1. Raw Ct values by variant and vaccination status. Raw Ct values (points) for individuals infected with (A) alpha, (B) delta, or (C) non-VOI-VOCs, and for (D) unvaccinated and (E) vaccinated individuals. Points are horizontally aligned so that the inferred mean peak viral concentration for each person occurs at time 0. Points that fall after the conclusion of an individual's acute infection, as measured by the individual's mean posterior infection clearance time, are partially transparent, as these were not the focus of our study. The inset illustrates the process of making the tail points transparent: black points depict viral concentration measurements for a single person and the solid black lines depict the individual's mean posterior viral trajectory.

263
264
265
266
267
268
269
270




271

272
273

274
275

276

277 **Figure 2. Estimated viral trajectory parameters for SARS-CoV-2 variants alpha and delta.** Individual
278 posterior means (points) with population means and 95% credible intervals (hatched lines) for (A) the peak
279 viral concentration, (B) the proliferation duration, (C) the clearance duration, and (D) the total duration of
280 acute infection for individuals infected with a non-VOI/VOC (light blue), alpha (red), or delta (orange). Cir-
281 cles denote unvaccinated individuals and triangles denote vaccinated individuals (breakthroughs). The
282 points are jittered horizontally to avoid overlap. Panes (E)-(F) depict the mean posterior viral trajectories for
283 alpha (E, red) and delta (F, orange) infections relative to non-VOI/VOC infections (light blue), as specified
284 by the population means and credible intervals in (A)-(D). Solid lines in panes (E)-(F) depict the mean
285 posterior viral trajectories and shaded regions represent 95% credible areas for the mean posterior trajec-
286 tories. Histograms in pane (G) depict the posterior distributions of peak Ct values aggregated across all
287 individuals infected with a non-VOI/VOC, alpha, and delta. The dashed line marks Ct = 15 (9.6 log₁₀ RNA
288 copies/ml) to facilitate comparison of the frequency of low peak Ct values/high peak viral concentrations
289 across variants.
290



291
292

293
294
295

296
297

298 **Figure 3. Estimated viral trajectory parameters for SARS-CoV-2 infections in unvaccinated and vac-**
 299 **cinated individuals.** Individual posterior means (points) with population means and 95% credible intervals
 300 (hatched lines) for (A) the peak viral concentration, (B) the proliferation duration, (C) the clearance duration,
 301 and (D) the total duration of acute infection for unvaccinated individuals (green) and vaccinated individuals
 302 (dark blue). Circles denote unvaccinated individuals and triangles denote vaccinated individuals (break-
 303 throughs). The points are jittered horizontally to avoid overlap. Pane (E) depicts the mean posterior viral
 304 trajectories for vaccinated individuals (green) relative to unvaccinated individuals (dark blue), as specified
 305 by the population means and credible intervals in (A)-(D). Solid lines in pane (E) depict the mean posterior
 306 viral trajectories and shaded regions represent 95% credible areas for the mean posterior trajectories.

307 References

- 308
- 309 1. Centers for Disease Control and Prevention. COVID Data Tracker. Published 2021. Accessed
310 May 20, 2021. <https://covid.cdc.gov/covid-data-tracker/>
- 311 2. Galloway SE, Paul P, MacCannell DR, Johansson MA, Brooks JT, MacNeil A, et al. Emergence of
312 SARS-CoV-2 B.1.1.7 Lineage — United States, December 29, 2020–January 12, 2021. *MMWR*
313 *Morb Mortal Wkly Rep.* 2021;70(3):95-99. doi:10.15585/mmwr.mm7003e2
- 314 3. Yi C, Sun X, Ye J, Ding L, Liu M, Yang Z, et al. Key residues of the receptor binding motif in the
315 spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. *Cell Mol*
316 *Immunol.* 2020;17(6):621-630. doi:10.1038/s41423-020-0458-z
- 317 4. Bailly B, Guilpain L, Bouiller K, Chirouze C, N'Debi M, Soulier A, et al. BNT162b2 Messenger RNA
318 Vaccination Did Not Prevent an Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2
319 Variant 501Y.V2 in an Elderly Nursing Home but Reduced Transmission and Disease Severity.
320 *Clin Infect Dis.* Published online May 16, 2021. doi:10.1093/cid/ciab446
- 321 5. Brinkley-Rubinstein L, Peterson M, Martin R, Chan P, Berk J. Breakthrough SARS-CoV-2
322 Infections in Prison after Vaccination. *N Engl J Med.* Published online July 7,
323 2021:NEJMc2108479. doi:10.1056/NEJMc2108479
- 324 6. Li B, Deng A, Li K, Hu Y, Li Z, Xiong Q, et al. Viral infection and transmission in a large, well-
325 traced outbreak caused by the SARS-CoV-2 Delta variant. *medRxiv.* Published online 2021.
- 326 7. Ke R, Martinez PP, Smith RL, Gibson LL, Mirza A, Conte M, et al. Daily sampling of early SARS-
327 CoV-2 infection reveals substantial heterogeneity in infectiousness. *medRxiv.* Published online
328 2021. doi:<https://www.medrxiv.org/content/10.1101/2021.07.12.21260208v1>
- 329 8. Chia PY, Ong SWX, Chiew CJ, Ang LW, Chavatte J-M, Mak T-M, et al. Virological and serological
330 kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study.
331 *medRxiv.* Published online 2021.
- 332 9. Brown CM, Vostok J, Johnson H, Burns M, Gharpure R, Sami S, et al. Outbreak of SARS-CoV-2
333 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public
334 Gatherings — Barnstable County, Massachusetts, July 2021. *MMWR Morb Mortal Wkly Rep.*
335 2021;70(31):1059-1062. doi:10.15585/mmwr.mm7031e2
- 336 10. Hay JA, Kennedy-Shaffer L, Kanjilal S, Lennon NJ, Gabriel SB, Lipsitch M, et al. Estimating
337 epidemiologic dynamics from cross-sectional viral load distributions. *Science (80-)*.
338 2021;373(6552):eabh0635. doi:10.1126/science.abh0635
- 339 11. United States Food and Drug Administration. *Emergency Use Authorization for TaqPath COVID-
340 19 Combo Kit.*; 2020. <https://www.fda.gov/media/136113/download>
- 341 12. Loman N, Rowe W, Rambaut A. nCoV-2019 novel coronavirus bioinformatics protocol.
- 342 13. Illumina. *Illumina COVIDSeq Test Instructions for Use.*; 2021.
343 <https://www.fda.gov/media/138776/download>
- 344 14. Illumina. NextSeq 550 System Documentation. Published 2021. Accessed June 10, 2021.
345 https://support.illumina.com/sequencing/sequencing_instruments/nextseq-550/documentation.html
- 346 15. BaseSpace Labs. DRAGEN COVID Lineage. Published online 2021.
- 347 16. Rambaut A, Holmes EC, O'Toole Á, Hill V, McCrone JT, Ruis C, et al. A dynamic nomenclature
348 proposal for SARS-CoV-2 lineages to assist genomic epidemiology. *Nat Microbiol.*
349 2020;5(11):1403-1407. doi:10.1038/s41564-020-0770-5
- 350 17. Aksamentov I, Neher R. NextClade. Published 2021. Accessed June 10, 2021.
351 <https://clades.nextstrain.org/>
- 352 18. Kissler SM, Fauver JR, Mack C, Olesen SW, Tai C, Shiue KY, et al. Viral dynamics of acute
353 SARS-CoV-2 infection and applications to diagnostic and public health strategies. *PLoS Biol.*
354 2021;19(7):1-17. doi:10.1371/journal.pbio.3001333
- 355 19. Carpenter B, Gelman A, Hoffman MD, Lee D, Goodrich B, Betancourt M, et al. Stan : A
356 Probabilistic Programming Language. *J Stat Softw.* 2017;76(1). doi:10.18637/jss.v076.i01
- 357 20. Kissler SM. Github Repository: CtTrajectories_AllVariants. Published 2021. Accessed June 14,
358 2021. https://github.com/gradlab/CtTrajectories_AllVariants
- 359 21. Gelman A, Carlin JB, Stern HS, Dunson DB, Vehtari A, Rubin DB. *Bayesian Data Analysis.* 3rd ed.

- 360 CRC Press; 2013.
- 361 22. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated
362 transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science* (80-).
363 2021;372(6538):eabg3055. doi:10.1126/science.abg3055
- 364 23. Mack CD, Wasserman EB, Perrine CG, MacNeil A, Anderson DJ, Myers E, et al. Implementation
365 and Evolution of Mitigation Measures, Testing, and Contact Tracing in the National Football
366 League, August 9–November 21, 2020. *MMWR Morb Mortal Wkly Rep.* 2021;70(4):130-135.
367 doi:10.15585/mmwr.mm7004e2
- 368 24. Fisman DN, Tuite AR. Progressive Increase in Virulence of Novel SARS-CoV-2 Variants in
369 Ontario, Canada. *medRxiv*. Published online 2021.
- 370 25. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the
371 mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med.* 2021;384(5):403-416.
372 doi:10.1056/NEJMoa2035389
- 373 26. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of
374 the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med.* 2020;383(27):2603-2615.
375 doi:10.1056/NEJMoa2034577
- 376 27. Oliver SE, Gargano JW, Scobie H, Wallace M, Hadler SC, Leung J, et al. The Advisory Committee
377 on Immunization Practices' Interim Recommendation for Use of Janssen COVID-19 Vaccine —
378 United States, February 2021. *MMWR Morb Mortal Wkly Rep.* 2021;70(9):329-332.
379 doi:10.15585/mmwr.mm7009e4
- 380 28. Andrejko KL, Pry J, Myers JF, Jewell NP, Openshaw J, Watt J, et al. Prevention of COVID-19 by
381 mRNA-based vaccines within the general population of California. *medRxiv*. Published online
382 2021.
- 383 29. Corchado-Garcia J, Puyraimond-Zemmour D, Hughes T, Cristea-Platon T, Lenehan P, Pawlowski
384 C, et al. Real-world effectiveness of Ad26.COV2.S adenoviral vector vaccine for COVID-19.
385 *medRxiv*. Published online 2021.
- 386 30. Pawlowski C, Lenehan P, Puranik A, Agarwal V, Venkatakrishnan A, Niesen MJM, et al. FDA-
387 authorized COVID-19 vaccines are effective per real-world evidence synthesized across a multi-
388 state health system. *medRxiv*. Published online 2021.
- 389 31. Singanayagam A, Patel M, Charlett A, Lopez Bernal J, Saliba V, Ellis J, et al. Duration of
390 infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19,
391 England, January to May 2020. *Euro Surveill.* 2020;25(32):1-5. doi:10.2807/1560-
392 7917.ES.2020.25.32.2001483
- 393 32. Butler D, Mozsary C, Meydan C, Foox J, Rosiene J, Shaiber A, et al. Shotgun transcriptome,
394 spatial omics, and isothermal profiling of SARS-CoV-2 infection reveals unique host responses,
395 viral diversification, and drug interactions. *Nat Commun.* 2021;12(1):1660. doi:10.1038/s41467-
396 021-21361-7
- 397 33. Kudo E, Israelow B, Vogels CBF, Lu P, Wyllie AL, Tokuyama M, et al. Detection of SARS-CoV-2
398 RNA by multiplex RT-qPCR. Sugden B, ed. *PLOS Biol.* 2020;18(10):e3000867.
399 doi:10.1371/journal.pbio.3000867
- 400 34. Vogels C, Fauver J, Ott IM, Grubaugh N. *Generation of SARS-COV-2 RNA Transcript Standards*
401 *for QRT-PCR Detection Assays.*; 2020. doi:10.17504/protocols.io.bdv6i69e
- 402 35. Cleary B, Hay JA, Blumenstiel B, Gabriel S, Regev A, Mina MJ. Efficient prevalence estimation
403 and infected sample identification with group testing for SARS-CoV-2. *medRxiv*. Published online
404 2020.
- 405 36. Tom MR, Mina MJ. To Interpret the SARS-CoV-2 Test, Consider the Cycle Threshold Value. *Clin*
406 *Infect Dis.* 2020;02115(Xx):1-3. doi:10.1093/cid/ciaa619
- 407 37. R Development Core Team R. R: A Language and Environment for Statistical Computing. Team
408 RDC, ed. *R Found Stat Comput.* 2011;1(2.11.1):409. doi:10.1007/978-3-540-74686-7
- 409 38. Kissler SM, Fauver JR, Mack C, Olesen SW, Tai C, Shiue KY, et al. Viral dynamics of acute
410 SARS-CoV-2 infection and applications to diagnostic and public health strategies. Riley S, ed.
411 *PLOS Biol.* 2021;19(7):e3001333. doi:10.1371/journal.pbio.3001333
- 412

413 **Supplementary Appendix.**

414

415 Converting Ct values to viral genome equivalents. To convert Ct values to viral genome
416 equivalents, we first converted the Roche cobas target 1 Ct values to equivalent Ct values on a
417 multiplexed version of the RT-qPCR assay from the US Centers for Disease Control and
418 Prevention.³³ We did this following our previously described methods.¹⁸ Briefly, we adjusted the
419 Ct values using the best-fit linear regression between previously collected Roche cobas target 1
420 Ct values and CDC multiplex Ct values using the following regression equation:

421

$$422 \quad y_i = \beta_0 + \beta_1 x_i + \epsilon_i \quad (S1)$$

423

424 Here, y_i denotes the i^{th} Ct value from the CDC multiplex assay, x_i denotes the i^{th} Ct value from the
425 Roche cobas target 1 test, and ϵ_i is an error term with mean 0 and constant variance across all
426 samples. The coefficient values are $\beta_0 = -6.25$ and $\beta_1 = 1.34$.

427

428 Ct values were fitted to a standard curve to convert Ct value data to RNA copies. Synthetic T7
429 RNA transcripts corresponding to a 1,363 b.p. segment of the SARS-CoV-2 nucleocapsid gene
430 were serially diluted from 10^6 - 10^0 RNA copies/ μl in duplicate to generate a standard curve³⁴
431 (**Supplementary Table 2**). The average Ct value for each dilution was used to calculate the slope
432 (-3.60971) and intercept (40.93733) of the linear regression of Ct on \log_{10} transformed standard
433 RNA concentration, and Ct values from subsequent RT-qPCR runs were converted to RNA copies
434 using the following equation:

435

$$436 \quad \log_{10}([\text{RNA}]) = (Ct - 40.93733)/(-3.60971) + \log_{10}(250) \quad (S2)$$

437

438 Here, [RNA] represents the RNA copies /ml. The $\log_{10}(250)$ term accounts for the extraction (300
439 μl) and elution (75 μl) volumes associated with processing the clinical samples as well as the
440 1,000 $\mu\text{l}/\text{ml}$ unit conversion.

441

442 Model fitting.

443 For the statistical analysis, we removed any sequences of 3 or more consecutive negative tests
444 (Ct = 40) to avoid overfitting to these trivial values. Following our previously described methods,¹⁸
445 we assumed that the viral concentration trajectories consisted of a proliferation phase, with

446 exponential growth in viral RNA concentration, followed by a clearance phase characterized by
447 exponential decay in viral RNA concentration.³⁵ Since Ct values are roughly proportional to the
448 negative logarithm of viral concentration³⁶, this corresponds to a linear decrease in Ct followed by
449 a linear increase. We therefore constructed a piecewise-linear regression model to estimate the
450 peak Ct value, the time from infection onset to peak (*i.e.* the duration of the proliferation stage),
451 and the time from peak to infection resolution (*i.e.* the duration of the clearance stage). The
452 trajectory may be represented by the equation

$$E[Ct(t)] = \begin{cases} \text{l.o.d.} & t \leq t_o \\ \text{l.o.d.} - \frac{\delta}{t_p - t_o}(t - t_o) & t_o < t \leq t_p \\ \text{l.o.d.} - \delta + \frac{\delta}{t_r - t_p}(t - t_p) & t_p < t \leq t_r \\ \text{l.o.d.} & t > t_r \end{cases} \quad (\text{S3})$$

454
455 Here, $E[Ct(t)]$ represents the expected value of the Ct at time t , “l.o.d” represents the RT-qPCR
456 limit of detection, δ is the absolute difference in Ct between the limit of detection and the peak
457 (lowest) Ct, and t_o , t_p , and t_r are the onset, peak, and recovery times, respectively.

458
459 Before fitting, we re-parametrized the model using the following definitions:

- 460
461
- 462 • $\Delta Ct(t) = \text{l.o.d.} - Ct(t)$ is the difference between the limit of detection and the observed Ct
 - 463 value at time t .
 - 464 • $\omega_p = t_p - t_o$ is the duration of the proliferation stage.
 - 465 • $\omega_r = t_r - t_p$ is the duration of the clearance stage.

466
467 We constrained $0.25 \leq \omega_p \leq 14$ days and $2 \leq \omega_r \leq 30$ days to prevent inferring unrealistically small
468 or large values for these parameters for trajectories that were missing data prior to the peak and
469 after the peak, respectively. We also constrained $0 \leq \delta \leq 40$ as Ct values can only take values
470 between 0 and the limit of detection (40).

471
472 We next assumed that the observed $\Delta Ct(t)$ could be described the following mixture model:

473

$$\Delta Ct(t) \sim \lambda \text{Normal}(E[\Delta Ct(t)], \sigma(t)) + (1 - \lambda) \text{Exponential}(\log(10)) \Big|_0^{\text{l.o.d}} \quad (\text{S4})$$

474

475
476 where $E[\Delta Ct(t)] = \text{l.o.d.} - E[Ct(t)]$ and λ is the sensitivity of the q-PCR test, which we fixed at 0.99.
477 The bracket term on the right-hand side of the equation denotes that the distribution was truncated
478 to ensure Ct values between 0 and the limit of detection. This model captures the scenario where
479 most observed Ct values are normally distributed around the expected trajectory with standard
480 deviation $\sigma(t)$, yet there is a small (1%) probability of an exponentially distributed false negative
481 near the limit of detection. The $\log(10)$ rate of the exponential distribution was chosen so that 90%
482 of the mass of the distribution sat below 1 Ct unit and 99% of the distribution sat below 2 Ct units,
483 ensuring that the distribution captures values distributed at or near the limit of detection. We did
484 not estimate values for λ or the exponential rate because they were not of interest in this study;
485 we simply needed to include them to account for some small probability mass that persisted near
486 the limit of detection to allow for the possibility of false negatives.

487
488 We used a hierarchical structure to describe the distributions of ω_p , ω_r , and δ for each person
489 based on their respective population means μ_{ω_p} , μ_{ω_r} , and μ_{δ} and population standard deviations
490 σ_{ω_p} , σ_{ω_r} , and σ_{δ} such that

$$\begin{aligned} 491 & \\ 492 & \omega_p \sim \text{Normal}(\mu_{\omega_p}, \sigma_{\omega_p}) \\ 493 & \omega_r \sim \text{Normal}(\mu_{\omega_r}, \sigma_{\omega_r}) \\ 494 & \delta \sim \text{Normal}(\mu_{\delta}, \sigma_{\delta}) \end{aligned} \tag{S5}$$

495
496 We inferred population means (μ) separately for individuals infected with alpha, delta, and non-
497 VOI/VOCs, as well as for unvaccinated and vaccinated individuals in a separate analysis. We
498 used a Hamiltonian Monte Carlo fitting procedure implemented in Stan (version 2.24)¹⁹ and R
499 (version 3.6.2)³⁷ to estimate the individual-level parameters ω_p , ω_r , δ , and t_p as well as the
500 population-level parameters σ^* , μ_{ω_p} , μ_{ω_r} , μ_{δ} , σ_{ω_p} , σ_{ω_r} , and σ_{δ} . We used the following priors:

501
502 *Hyperparameters:*

$$503 \quad \sigma^* \sim \text{Cauchy}(0, 5) [0, \infty] \tag{S6}$$

$$\begin{aligned} 504 & \mu_{\omega_p} \sim \text{Normal}(2.7, 14/6) [0.25, 14] \\ 505 & \mu_{\omega_r} \sim \text{Normal}(7.4, 30/6) [2, 30] \end{aligned} \tag{S7}$$

508 $\mu_{\delta} \sim \text{Normal}(20, 40/6) [0, 40]$.

509
510 $\sigma_{\omega_p} \sim \text{Cauchy}(0, 14/\tan(\pi(0.95-0.5))) [0, \infty]$ (S8)

511 $\sigma_{\omega_r} \sim \text{Cauchy}(0, 30/\tan(\pi(0.95-0.5))) [0, \infty]$

512 $\sigma_{\delta} \sim \text{Cauchy}(0, 40/\tan(\pi(0.95-0.5))) [0, \infty]$

513
514 *Individual-level parameters:*
515 $\omega_p \sim \text{Normal}(\mu_{\omega_p}, \sigma_{\omega_p}) [0.25, 14]$
516 $\omega_r \sim \text{Normal}(\mu_{\omega_r}, \sigma_{\omega_r}) [2, 30]$ (S9)

517 $\delta \sim \text{Normal}(\mu_{\delta}, \sigma_{\delta}) [0, 40]$

518 $t_p \sim \text{Normal}(0, 2)$

519
520 The values in square brackets denote truncation bounds for the distributions. We chose a vague
521 half-Cauchy prior with scale 5 for the observation variance σ^* . The priors for the population mean
522 values (μ .) are normally distributed priors spanning the range of allowable values for that
523 parameter; this prior is vague but expresses a mild preference for values near the posterior
524 estimates obtained from a previous analysis.³⁸ The priors for the population standard deviations
525 (σ .) are half Cauchy-distributed with scale chosen so that 90% of the distribution sits below the
526 maximum value for that parameter; this prior is vague but expresses a mild preference for
527 standard deviations close to 0.

528
529 We ran four MCMC chains for 2,000 iterations each with a target average proposal acceptance
530 probability of 0.8. The first half of each chain was discarded as the warm-up. The Gelman R-hat
531 statistic was less than 1.1 for all parameters. This indicates good overall mixing of the chains.
532 There were no divergent iterations, indicating good exploration of the parameter space. The
533 posterior distributions for μ_{δ} , μ_{ω_p} , and μ_{ω_r} , were estimated separately for individuals infected with
534 alpha, delta, and non-VOI/VOCs as well as for vaccinated and unvaccinated individuals. These
535 are depicted in **Figure 1** (main text). Draws from the individual posterior viral trajectory
536 distributions are depicted in **Supplementary Figures 1-11**. The mean posterior viral trajectories
537 for each person are depicted in **Supplementary Figure 12**.

538
539 Assessing sensitivity to different priors.

540 To ensure that our findings were not overly influenced by the prior distributions, we re-fit the model
541 using two different sets of priors. The first “vague” set used posterior population means for $\mu_{\omega p}$,
542 $\mu_{\omega r}$, and μ_{δ} chosen to lie near the center of the allowable range for those parameters. These priors
543 were defined by

$$\begin{aligned} 544 & \mu_{\omega p} \sim \text{Normal}(14/2, 14/6) [0.25, 14] \\ 545 & \mu_{\omega r} \sim \text{Normal}(30/2, 30/6) [2, 30] \\ 546 & \mu_{\delta} \sim \text{Normal}(40/2, 40/6) [0, 40] \end{aligned} \tag{S10}$$

548
549 The second set used unrealistically low prior means for $\mu_{\omega p}$, $\mu_{\omega r}$, and μ_{δ} to check model robustness
550 to highly biased prior distributions. These priors were defined by

$$\begin{aligned} 551 & \mu_{\omega p} \sim \text{Normal}(0, 14/6) [0.25, 14] \\ 552 & \mu_{\omega r} \sim \text{Normal}(0, 30/6) [2, 30] \\ 553 & \mu_{\delta} \sim \text{Normal}(20, 40/6) [0, 40]. \end{aligned} \tag{S11}$$

554
555
556 Note that we updated the prior means but kept the prior variances at their original wide values to
557 avoid encoding over-confidence in the priors into the model. The posterior population means for
558 these new sets of priors are depicted in **Supplementary Figures 13-14** (compare to **Figures 2-**
559 **3**). Overall, the findings were consistent across choices of prior.

560

	Minimum Ct	Maximum viral concentration (log₁₀ RNA copies/ml)	Proliferation duration (days)	Clearance duration (days)	Acute infection duration (days)
Non-VOI/VOC	20.1 [18.3, 21.7]	8.2 [7.7, 11.6]	4.2 [3.3, 5.2]	7.3 [6.1, 8.4]	11.4 [10.1, 12.8]
Alpha	21.0 [19.1, 20.9]	7.9 [8.0, 11.5]	3.4 [2.6, 4.5]	6.2 [5.2, 7.4]	9.6 [8.3, 11.1]
Delta	19.8 [18.0, 22.0]	8.3 [7.7, 11.6]	3.0 [2.2, 4.0]	6.2 [5.2, 7.4]	9.2 [8.0, 10.6]
Unvaccinated	20.7 [19.8, 20.2]	8.0 [8.2, 11.5]	3.5 [3.0, 4.0]	7.5 [6.8, 8.2]	11.0 [10.3, 11.8]
Vaccinated	20.5 [19.0, 21.0]	8.1 [7.9, 11.5]	3.2 [2.5, 4.0]	5.5 [4.6, 6.5]	8.7 [7.6, 9.9]

561

562

563 **Supplementary Table 1. Posterior population viral trajectory parameters for SARS-CoV-2 infections**
564 **by variant and vaccination status.** Reported values represent the posterior mean and 95% credible
565 intervals (brackets) for each parameter.

566


567

Standard (copies/ul)	Replicate 1 (Ct)	Replicate 2 (Ct)	Average Ct
10⁶	19.3	19.7	19.5
10⁵	23.0	21.2	22.1
10⁴	26.9	26.7	26.8
10³	30.6	30.4	30.5
10²	34.0	34.0	34.0
10¹	37.2	36.6	36.9
10⁰	N/A	39.9	39.9

568

569 **Supplementary Table 2. Standard curve relationship between virus RNA copies and Ct values.**
570 Synthetic T7 RNA transcripts corresponding to a 1,363 base pair segment of the SARS-CoV-2 nucleocapsid
571 gene were serially diluted from 10⁶-10⁰ and evaluated in duplicate with RT-qPCR. The best-fit linear
572 regression of the average Ct on the log₁₀-transformed standard values had slope -3.60971 and intercept
573 40.93733 (R² = 0.99).
574

575



576

577

578 **Supplementary Figure 1. Ct values and estimated trajectories for non-VOI/VOIC SARS-CoV-2 infections (1/3).**

579 Each pane depicts the recorded Ct values (points) and derived log-10 genome equivalents per


580 ml ($\log_{10}(\text{ge/ml})$) for a single person during the study period. Points along the horizontal axis represent neg-

581 ative tests. Time is indexed in days since the minimum recorded Ct value (maximum viral concentration).

582 Lines depict 100 draws from the posterior distribution for each person's viral trajectory. Shaded boxes de-


583 note breakthrough infections.

584




585
586
587
588
589
590
591
592
593
594
595
596
597
598

Supplementary Figure 2. Ct values and estimated trajectories for non-VOI/VOIC SARS-CoV-2 infections (2/3). Each pane depicts the recorded Ct values (points) and derived log-10 genome equivalents per ml ($\log(\text{ge/ml})$) for a single person during the study period. Points along the horizontal axis represent negative tests. Time is indexed in days since the minimum recorded Ct value (maximum viral concentration). Lines depict 100 draws from the posterior distribution for each person's viral trajectory. Shaded boxes denote breakthrough infections.




599
600
601
602
603
604
605
606
607
608

Supplementary Figure 3. Ct values and estimated trajectories for alpha SARS-CoV-2 infections. Each pane depicts the recorded Ct values (points) and derived log-10 genome equivalents per ml ($\log_{10}(\text{ge/ml})$) for a single person during the study period. Points along the horizontal axis represent negative tests. Time is indexed in days since the minimum recorded Ct value (maximum viral concentration). Lines depict 100 draws from the posterior distribution for each person's viral trajectory. Shaded boxes denote breakthrough infections.




609
610
611
612
613
614
615
616
617

Supplementary Figure 4. Ct values and estimated trajectories for delta SARS-CoV-2 infections. Each pane depicts the recorded Ct values (points) and derived log-10 genome equivalents per ml (log₁₀(ge/ml)) for a single person during the study period. Points along the horizontal axis represent negative tests. Time is indexed in days since the minimum recorded Ct value (maximum viral concentration). Lines depict 100 draws from the posterior distribution for each person's viral trajectory. Shaded boxes denote breakthrough infections.




618
619
620
621
622
623
624
625

Supplementary Figure 5. Ct values and estimated trajectories for SARS-CoV-2 infections in unvaccinated individuals (1/4). Each pane depicts the recorded Ct values (points) and derived log-10 genome equivalents per ml ($\log(\text{ge/ml})$) for a single person during the study period. Points along the horizontal axis represent negative tests. Time is indexed in days since the minimum recorded Ct value (maximum viral concentration). Lines depict 100 draws from the posterior distribution for each person's viral trajectory.




Supplementary Figure 6. Ct values and estimated trajectories for SARS-CoV-2 infections in unvaccinated individuals (2/4). Each pane depicts the recorded Ct values (points) and derived log-10 genome equivalents per ml ($\log_{10}(\text{ge/ml})$) for a single person during the study period. Points along the horizontal axis represent negative tests. Time is indexed in days since the minimum recorded Ct value (maximum viral concentration). Lines depict 100 draws from the posterior distribution for each person's viral trajectory.




634
635
636
637
638
639
640
641

Supplementary Figure 7. Ct values and estimated trajectories for SARS-CoV-2 infections in unvaccinated individuals (3/4). Each pane depicts the recorded Ct values (points) and derived log-10 genome equivalents per ml ($\log_{10}(\text{ge/ml})$) for a single person during the study period. Points along the horizontal axis represent negative tests. Time is indexed in days since the minimum recorded Ct value (maximum viral concentration). Lines depict 100 draws from the posterior distribution for each person's viral trajectory.



642
643
644
645
646
647
648
649


Supplementary Figure 8. Ct values and estimated trajectories for SARS-CoV-2 infections in unvaccinated individuals (4/4). Each pane depicts the recorded Ct values (points) and derived log-10 genome equivalents per ml ($\log(\text{ge/ml})$) for a single person during the study period. Points along the horizontal axis represent negative tests. Time is indexed in days since the minimum recorded Ct value (maximum viral concentration). Lines depict 100 draws from the posterior distribution for each person's viral trajectory.




650
651
652
653
654
655
656
657
658

Supplementary Figure 9. Ct values and estimated trajectories for SARS-CoV-2 infections in vaccinated individuals. Each pane depicts the recorded Ct values (points) and derived log-10 genome equivalents per ml ($\log(\text{ge/ml})$) for a single person during the study period. Points along the horizontal axis represent negative tests. Time is indexed in days since the minimum recorded Ct value (maximum viral concentration). Lines depict 100 draws from the posterior distribution for each person's viral trajectory. Shaded boxes denote breakthrough infections.

659




660
661
662
663



664
665
666
667
668
669
670
671
672
673
674
675
676

Supplementary Figure 10. Estimated viral trajectory parameters for vaccinated and unvaccinated individuals infected with SARS-CoV-2 variant delta. Individual posterior means (points) with population means and 95% credible intervals (hatched lines) for (A) the peak viral concentration, (B) the proliferation duration, (C) the clearance duration, and (D) the total duration of acute infection for unvaccinated (blue) and vaccinated (red) individuals infected with delta. Circles denote unvaccinated individuals and triangles denote vaccinated individuals (breakthroughs). The points are jittered horizontally to avoid overlap. Pane (E) depicts the mean posterior viral trajectories for unvaccinated (blue) vs. vaccinated (red) individuals, as specified by the population means and credible intervals in (A)-(D). Solid lines in pane (E) depict the mean posterior viral trajectories and shaded regions represent 95% credible areas for the mean posterior trajectories.




677
678

679
680

681
682
683
684
685
686
687
688
689
690
691
692
693
694
695

Supplementary Figure 11. Estimated viral trajectory parameters for individuals vaccinated with the Pfizer-BioNTech vaccine vs. the Johnson & Johnson/Janssen vaccine. Individual posterior means (points) with population means and 95% credible intervals (hatched lines) for (A) the peak viral concentration, (B) the proliferation duration, (C) the clearance duration, and (D) the total duration of acute infection for breakthrough infections in individuals vaccinated with the Pfizer-BioNTech vaccine (blue) and the Johnson & Johnson/Janssen vaccine (red). The points are jittered horizontally to avoid overlap. Pane (E) depicts the mean posterior viral trajectories for breakthrough infections in individuals vaccinated with the Pfizer-BioNTech vaccine (blue) vs. the Johnson & Johnson/Janssen vaccine (red), as specified by the population means and credible intervals in (A)-(D). Solid lines in pane (E) depict the mean posterior viral trajectories and shaded regions represent 95% credible areas for the mean posterior trajectories.


696
697



698
699
700


701
702
703
704
705
706
707
708

Supplementary Figure 12. Mean posterior viral trajectories for each person. Pane (A) depicts alpha infections (red) against non-VOI/VOC infections (blue). Pane (B) depicts delta infections (red) against non-VOI/VOC infections (blue). Pane (C) depicts infections in vaccinated people (red) against unvaccinated people (blue). Trajectories are aligned temporally to have the same peak time.




709

710
711
712
713




714



715
716

717 **Supplementary Figure 13. Estimated viral trajectory parameters for SARS-CoV-2 infections by vari-**
718 **ant and vaccination status using uninformative priors.** Individual posterior means (points) with popula-
719 tion means and 95% credible intervals (hatched lines) for (A) the peak viral concentration, (B) the prolifer-
720 ation duration, (C) the clearance duration, and (D) the total duration of acute infection for individuals infected
721 with a non-VOI/VOC (blue), alpha (red), or delta (purple), and for individuals who were unvaccinated (green)
722 or vaccinated (maroon). Circles denote unvaccinated individuals and triangles denote vaccinated individu-
723 als (breakthroughs). The points are jittered horizontally to avoid overlap. Solid lines in panes (E)-(F) depict
724 the mean posterior viral trajectories for alpha (E, red) and delta (F, purple) infections respectively relative
725 to non-VOI/VOC infections (blue), as specified by the population means and credible intervals in (A)-(D).
726 Solid lines in pane (G) depict the mean posterior viral trajectory for vaccinated (maroon) relative to unvac-
727 cinated (green) individuals. The shaded regions in (E)-(G) represent 95% credible areas for the mean pop-
728 ulation trajectories. Priors were informed by a previous analysis and are defined in Eq. (S10).
729



730

731
732
733

734
735

736
737

738 **Supplementary Figure 14 Estimated viral trajectory parameters for SARS-CoV-2 infections by vari-**
739 **ant and vaccination status using biased (low) priors.** Individual posterior means (points) with population
740 means and 95% credible intervals (hatched lines) for (A) the peak viral concentration, (B) the proliferation
741 duration, (C) the clearance duration, and (D) the total duration of acute infection for individuals infected with
742 a non-VOI/VOC (blue), alpha (red), or delta (purple), and for individuals who were unvaccinated (green) or
743 vaccinated (maroon). Circles denote unvaccinated individuals and triangles denote vaccinated individuals
744 (breakthroughs). The points are jittered horizontally to avoid overlap. Solid lines in panes (E)-(F) depict the
745 mean posterior viral trajectories for alpha (E, red) and delta (F, purple) infections respectively relative to
746 non-VOI/VOC infections (blue), as specified by the population means and credible intervals in (A)-(D). Solid
747 lines in pane (G) depict the mean posterior viral trajectory for vaccinated (maroon) relative to unvaccinated
748 (green) individuals. The shaded regions in (E)-(G) represent 95% credible areas for the mean population
749 trajectories. Priors were chosen to be unrealistically low and are defined in Eq. (S11).
750